Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Current Assets (2016 - 2025)

Historic Current Assets for Haemonetics (HAE) over the last 16 years, with Q4 2025 value amounting to $943.7 million.

  • Haemonetics' Current Assets fell 618.31% to $943.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $943.7 million, marking a year-over-year decrease of 618.31%. This contributed to the annual value of $935.0 million for FY2025, which is 2159.86% up from last year.
  • Latest data reveals that Haemonetics reported Current Assets of $943.7 million as of Q4 2025, which was down 618.31% from $899.7 million recorded in Q3 2025.
  • Haemonetics' Current Assets' 5-year high stood at $1.0 billion during Q4 2024, with a 5-year trough of $684.4 million in Q3 2021.
  • In the last 5 years, Haemonetics' Current Assets had a median value of $769.3 million in 2023 and averaged $813.8 million.
  • Per our database at Business Quant, Haemonetics' Current Assets plummeted by 988.16% in 2021 and then soared by 3148.91% in 2024.
  • Over the past 5 years, Haemonetics' Current Assets (Quarter) stood at $699.2 million in 2021, then grew by 1.01% to $706.3 million in 2022, then increased by 8.31% to $765.0 million in 2023, then skyrocketed by 31.49% to $1.0 billion in 2024, then decreased by 6.18% to $943.7 million in 2025.
  • Its Current Assets stands at $943.7 million for Q4 2025, versus $899.7 million for Q3 2025 and $913.2 million for Q2 2025.